Lucid Diagnostics financials
$0.7510−7.17%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377.0K | $500.0K |
| Gross profit | -$2.0M | -$2.8M | -$3.6M | -$3.2M | -$85.0K |
| Gross margin | −41.7% | −63.3% | −146.3% | −858.6% | −17.0% |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M |
| Net income | -$70.6M | -$53.0M | -$52.7M | -$56.2M | -$28.1M |
| Net margin | −1499.6% | −1220.1% | −2169.1% | −14899.5% | −5615.6% |
| Diluted EPS | $-0.69 | $-1.05 | $-1.26 | $-1.55 | $-1.51 |
| EBITDA | -$48.8M | -$44.9M | -$46.0M | -$54.3M | -$27.4M |
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M |
| Free cash flow | -$46.7M | -$44.4M | -$33.0M | -$33.8M | -$18.5M |
| Diluted shares | 101.9M | 50.5M | 41.8M | 36.2M | 18.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $34.7M | $22.4M | $18.9M | $22.5M | $53.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $24.0M | $18.6M | $13.9M | $0.00 | $0.00 |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M |
| Shareholders' equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology